Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study
Co-administration of ExPEC9V with HD influenza vaccine met non-inferiority criteria of humoral immune responses for influenza antigens, but not for ExPEC9V O-serotype antigens. ExPEC9V, administered alone or with HD influenza vaccine, was safe and well tolerated, with an acceptable reactogenicity profile.
Authors
- Michal Sarnecki (ORCID: https://orcid.org/0000-0001-7035-0020)
- Keira A. Cohen (ORCID: https://orcid.org/0000-0002-4521-397X)
- Jeroen Stoop
- Chelsea Mclean
- Monika Peeters
- Sofie Deleu (ORCID: https://orcid.org/0009-0004-1272-8477)
- Maria Grazia Pau (ORCID: https://orcid.org/0000-0002-8995-9693)
- Todd Davies
- Bart Spiessens
- Tracey A. Day
- Oscar Go
Institutions
- Johnson & Johnson (United States) (US)
- Ghent University Hospital (BE)
- Johnson & Johnson (Switzerland) (CH)
- Johnson & Johnson (Netherlands) (NL)
Publication Details
- Journal
- Vaccines
- Published
- 2026-01-30
- DOI
- https://doi.org/10.3390/vaccines14020146
- Primary Topic
- Escherichia coli research studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi